Ontogeny of Vaccine-Induced Measles Immunity Child Participant-6 and 9 Months

This is an immunogenicity study evaluating the development of the immune response of healthy infants following primary vaccination with Attenuvax at 6 or 9 months of age compared with responses in 12 month-old infants receiving MMR-II. Responses of infants receiving an early two dose measles vaccine regimen with the first dose given at 6 or 9 months followed by a second dose administered at 12 months will also be compared to infants given a single dose at 12 months of age (Table 2). The current approved regimen for measles vaccination is a first vaccination at 12-15 months and a subsequent vaccination at school entry. A secondary endpoint of this study will be to assess the safety of measles vaccine administered as Attenuvax at 6 or 9 months of age and in an early two dose measles vaccine regimen with Attenuvax administered at 6 or 9 months followed by MMR-II at 12 months of age.

Stanford is now accepting new patients for this trial. Please contact Hayley Gans, MD at 650-723-5682 for more information.



  • biological : MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)
  • biological : Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous)

Phase: N/A


Ages Eligible For Study:

6 Months - N/A

Inclusion Criteria

Subjects must meet all of the following criteria in order to be enrolled: 1. Healthy infants 6, 9, or 12 months (+ 3 weeks) of age 2. Free of obvious health problems as established by medical history and clinical examination before entering into the study 3. Parent/legal guardian willing and capable of signing written informed consent 4. Parent/legal guardian expected to be available for entire study 5. Parent/legal guardian can be reached by telephone

External Links

Explore related trials

Contact information

Primary Contact:

Hayley Gans, MD 650-723-5682

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: